Skip to main content

Court of Appeals Reinstates Birmingham Hip Implant Lawsuit

Court of Appeals Reinstates Birmingham Hip Implant Lawsuit

Court of Appeals Reinstates Birmingham Hip Implant Lawsuit

Introduction

The 9th Circuit U.S. Court of Appeals confirmed on restoring a Birmingham Hip Resurfacing lawsuit filed by a plaintiff against Smith & Nephew alleging the manufacturer of failing to warn about the system's health risk.

The lawsuit, filed by the plaintiff in April 2016, indicates the hip implants were defective and not compliant to the federal Food, Drug and Cosmetics Act and its regulations. The case was dismissed by the district court which was reinstated by a common three-judge appeals court panel. The Court of Appeals states that the plaintiff’s proposed amended complaint sufficiently alleges a failure-to-warn claim under Arizona law.

Several Birmingham Hip Replacement lawsuits are federally-filed against Smith & Nephew, 140 of which have been combined into a major federal litigation. Hip replacement lawsuits continue to be filed under a related hip litigation involving Stryker Hip Replacement lawsuits, centralized before U.S. District Judge Indira Talwani under MDL No. 2768 – in Re: Stryker LFIT V40 Femoral Head Products Liability Litigation.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!